COVID-19 liver damage. Features of laboratory and instrumental diagnostics

The aim of the study - to analyze the pathogenesis of liver damage in COVID-19, as well as to study the features of diagnosis. Research materials: literature and own data on the peculiarities of the pathogenesis of liver damage were analyzed, as well as an assessment of laboratory and instrumental diagnostics in patients with COVID-19. The results of the research. In patients, liver damage was manifested by an increase in liver enzymes, as well as a diffuse decrease in its density during CT. The severity of the disease is caused by a cytokine storm caused by a dysfunctional immune response to the virus, viral virulence factors, as well as the presence of concomitant diseases, especially those associated with liver pathology, such as cirrhosis or steatosis. Conclusions. The new COVID-19 coronavirus infection caused by SARS-CoV-2 continues to spread worldwide. The main target is the organs of the respiratory system. However, among the patients with COVID-19, there were lesions of the central nervous system, intestines, myocardium and liver. Liver dysfunction in most cases should be considered as a result of secondary damage due to CVD, ARDS, hypoxia, multiple organ failure, exposure to immune factors, and taking hepatotoxic drugs.

liver, COVID-19, SARS-CoV-2, ACE-2, steatosis, CT

1. Lee IC, Huo TI, Huang YH. Gastrointestinal and liver manifestations in patients with COVID-19. J Chin Med Assoc. 2020 Jun;83(6):521-523. doi: 10.1097/JCMA.0000000000000319.

2. Zairatiants O.V. Pathological anatomy of COVID-19. Atlas. Moscow., DZM, 2020. 116 p. (in Russ.)@@ Патологическая анатомия COVID-19. Атлас / Под общей ред. Зайратьянца О.В. М.: ДЗМ, 2020. 116 c.

3. Hoffmann M., Kleine-Weber H., Schroeder S. et al. SARSCoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181 (2): 271-280.e8. doi: 10.1016/j.cell.2020.02.052.

4. Cai Q., Huang D., Yu H. et al. COVID-19: Abnormal liver function tests. J. Hepatol. 2020; S0168-8278(20)30218-X. doi: 10.1016/j.jhep.2020.04.006

5. Zhang C., Shi L., Wang F.S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol. Hepatol. 2020; 5 (5): 428-430. doi: 10.1016/S2468-1253(20)30057-1.

6. Chai X., Hu L., Zhang Y., Han W., Lu Z., Ke A. Specific ACE2expression in cholangiocytes may cause liver damageafter 2019-nCoV infection. bioRxiv. 2020;02(03):931766. doi: 10.1101/2020.02.03.931766.

7. Garrido I., Liberal R., Macedo G. Review article: COVID-19 and liver disease - what we know on 1st May 2020. Aliment Pharmacol. Ther. 2020 Jul;52(2):267-275. doi: 10.1111/apt.15813.

8. Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distresssyndrome. Lancet Respir. Med. 2020; 8 (4): 420-422. doi: 10.1016/S2213-2600(20)30076-X.

9. Zhang Y., Zheng L., Liu L., Zhao M., Xiao J., Zhao Q. Liverimpairment in COVID-19 patients: A retrospective analysisof 115 cases from a single centre in Wuhan city. Liver Int. 2020; 10.1111/liv.14455. doi: 10.1111/liv.14455.

10. Lai C.C., Shih T.P., Ko W.C., Tang H.J., Hsueh P.R. Severeacute respiratory syndrome coronavirus 2 (SARSCoV-2) and coronavirus disease-2019 (COVID-19): Theepidemic and the challenges.Int. J. Antimicrob. Agents. 2020; 55 (3): 105924. doi: 10.1016/j.ijantimicag.2020.105924.

11. Shi J., Li Y., Zhou X. et al. Lactate dehydrogenase and susceptibility to deteriorationof mild COVID-19 patients: a multicenter nested casecontrolstudy. BMC Med. 2020; 18 (1): 168. doi: 10.1186/s12916-020-01633-7

12. Liu X., Shi S., Xiao J. et al. Prediction of the severity ofCorona Virus Disease 2019 and its adverse clinical outcomes. Jpn J Infect Dis. 2020 Nov 24;73(6):404-410. doi: 10.7883/yoken.JJID.2020.194.

13. Arablinsky A.V., Chechenov M.Kh. Possibilities of computed tomography and computed tomographic angiography methods in the diagnosis of varying severity of fatty infiltration of the liver. Diagnostic and interventional radiology. 2009; 3 (3): 9-19. (in Russ.)@@ Араблинский А.В., Чеченов М.Х. Возможности методов компьютерной томографии и компьютерно-томографической ангиографии в диагностике различной выраженности жировой инфильтрации печени. Диагностическая и интервенционная радиология. 2009; 3 (3): 9-19.

14. Davydova A.V. Biochemical blood test in the differential diagnosis of liver diseases: A textbook for doctors. State Budgetary Educational Institution of Higher Professional Education of the Institute of State Medical University of the Ministry of Health of Russia. Irkutsk: IGMU, 2013. 64 p. (in Russ.)@@ Давыдова А.В. Биохимический анализ крови в дифференциальной диагностике заболеваний печени:Учебное пособие для врачей. ГБОУ ВПО ИГМУМинздрава России. Иркутск: ИГМУ, 2013. 64 с.

15. Koryachkin V.A., Emanuel V.L., Strashnov V.I. Diagnostic activity: a textbook for secondary vocational education. 2nd edition, revised and additional Moscow. Yurayt Publishing House, 2019. 462 p. (in Russ.)@@ Корячкин В.А., Эмануэль В.Л., Страшнов В.И. Диагностическая деятельность: учебник для СПО. 2-еизд., испр. и доп. М.: Изд-во Юрайт, 2019. 462 с.

16. Prompetchara E., Ketloy C., Palaga T. Immune responsesin COVID-19 and potential vaccines: Lessons learnedfrom SARS and MERS epidemic. Asian Pac. J. AllergyImmunol. 2020; 38 (1): 1-9. doi: 10.12932/AP-200220-0772.

17. Feng G., Zheng K.I., Yan Q.Q., Rios R.S., Targher G., Byrne C.D., Poucke S.V., Liu W.Y., Zheng M.H. COVID-19and Liver Dysfunction: Current Insights and EmergentTherapeutic Strategies. J. Clin. Transl. Hepatol. 2020;8 (1): 18-24. doi: 10.14218/JCTH.2020.00018.

18. Zhang X.J., Cheng X., Yan Z.Z. et al. An ALOX12-12-HETE-GPR31 signaling axis is a key mediator of hepaticischemia-reperfusion injury. Nat. Med. 2018; 24 (1): 73-83. doi: 10.1038/nm.4451.

19. Bangash M.N., Patel J., Parekh D. COVID-19 and the liver:little cause for concern. Lancet Gastroenterol. Hepatol.2020; S2468-1253(20)30084-4. doi: 10.1016/S2468-1253(20)30084-4.

20. O’Grady J.G., Alexander G.J., Hayllar K.M., Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989; 97: 439-445.

21. Bessems J.G., Vermeulen N.P. Paracetamol (acetaminophen)-induced toxicity: molecular andbiochemical mechanisms, analogues and protectiveapproaches. Crit. Rev. Toxicol. 2001 Jan;31(1):55-138. doi: 10.1080/20014091111677.